27-09-2021, 09:05 AM
The WHO was joined by Doctors Without Borders in expressing concerns about the high cost of the treatment.
The combination of two drugs, the monoclonal antibodies casirivimab and imdevimab, bind to the SARS-CoV-2 spike protein, neutralizing the virus and preventing it from infecting more cells. It is only the third treatment to be approved for treatment of COVID-19 by the WHO.
Japan was first to authorize its use last July. The European Union, US, India, Switzerland and Canada have already approved the drug combination for emergency use.
https://www.dw.com/en/coronavirus-digest...a-59292669
The combination of two drugs, the monoclonal antibodies casirivimab and imdevimab, bind to the SARS-CoV-2 spike protein, neutralizing the virus and preventing it from infecting more cells. It is only the third treatment to be approved for treatment of COVID-19 by the WHO.
Japan was first to authorize its use last July. The European Union, US, India, Switzerland and Canada have already approved the drug combination for emergency use.
https://www.dw.com/en/coronavirus-digest...a-59292669